Trial Information

Summary: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)

Status: Completed

Protocol Number: ML18092

Sponsor: Roche Bulgaria EOOD

Company Division: Pharmaceutical

Official Scientific Title: An open-label, non-randomized study to evaluate the effect of PEGASYS on HBV-DNA in patients with HBeAg-negative chronic hepatitis B infection

Brief Summary: This study will evaluate the efficacy, safety, and tolerability of PEGASYS in patients with HBeAg-negative chronic HBV. The anticipated time on study treatment is 3-12 months, and the target sample size is <100 individuals. Target sample size is 50.

Study Phase: IV

Study Design / Study Details:

  • Purpose: Treatment
  • Allocation: Non-Randomized
  • Masking: Open Label
  • Control: Uncontrolled
  • Assignment: Single Group
  • Endpoints: Safety/Efficacy

Study Type:

Interventional

Condition: Hepatitis B, Chronic

Intervention Type: Drug

Intervention Name: peginterferon alfa-2a (40KD)[PEGASYS]

Primary Outcome: 1. Efficacy: HBV-DNA <20,000 copies/mL at end of follow-up, normalization of ALT values at end of follow-up.Safety: AEs, laboratory parameters

Key Secondary Outcomes: 1. Efficacy: Loss of HBsAg and seroconversion at end of follow-up, HBV-DNA below limit of quantification at end of follow-up, HBV-DNA suppression <20,000 copies/mL at treatment end, ALT normalization at treatment end

Inclusion Criteria:

  • adult patients 18-70 years of age;
  • positive test result for HBsAg for >6 months;
  • naive to treatment for HBV;
  • on liver biopsy, liver disease consistent with chronic HBV, with or without compensated cirrhosis.

Exclusion Criteria:

  • co-infection with hepatitis A, C or D, or with human immunodeficiency virus (HIV);
  • decompensated liver disease;
  • hepatocellular cancer;
  • systemic anti-viral, anti-neoplastic, or immunomodulatory therapy <=6 months before study drug;
  • medical condition associated with chronic liver disease.

Gender: Males or Females

Age Limits: Min: 18 Years Max: 70 Years

Accepts Healthy Volunteers: No

Trial Registration Date: 10/28/2005

Date Last Updated: 08/18/2008

Link To Trial Results

Contact:

Research Site:
Located In:
Plovdiv, Bulgaria, 4002
Telephone: 973-235-5000 or 800-526-6367

 

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: August 20, 2008 at 2:16:37 PM


Back to Centerwatch Trial Listing by Location


Additional resources
in this illness area

Copyright © 1995 - 2008, CenterWatch
All Rights Reserved

This site was developed in association with Illumina Interactive, Boston, MA